Berlin: Bayer has received approval from the European Commission (EC) for a label extension in the European Union (EU) for ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME: Berlin Saturday, June 28, 2025, 09:00 Hrs [IST] The Eur ...

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME.

What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

So a very meaningful expansion opportunity for EYLEA HD and potentially could be the only product approved with every 8-week dosing. And lastly, every 4-week dosing is another label enhancement we ...